Balance Sheet
AssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Total Liabilities (2019 - 2025)

Benitec Biopharma's Total Liabilities history spans 7 years, with the latest figure at -$97.6 million for Q1 2025.

  • For Q1 2025, Total Liabilities fell 2888.51% year-over-year to -$97.6 million; the TTM value through Mar 2025 reached -$97.6 million, down 2888.51%, while the annual FY2024 figure was $5.0 million, 16.42% up from the prior year.
  • Total Liabilities for Q1 2025 was -$97.6 million at Benitec Biopharma, down from $3.1 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $5.9 million in Q4 2023 and bottomed at -$97.6 million in Q1 2025.
  • The 5-year median for Total Liabilities is $3.1 million (2022), against an average of -$7.7 million.
  • The largest annual shift saw Total Liabilities soared 258.29% in 2021 before it tumbled 2888.51% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $3.2 million in 2021, then crashed by 383.01% to -$9.0 million in 2022, then surged by 165.41% to $5.9 million in 2023, then tumbled by 46.85% to $3.1 million in 2024, then plummeted by 3220.24% to -$97.6 million in 2025.
  • Per Business Quant, the three most recent readings for BNTC's Total Liabilities are -$97.6 million (Q1 2025), $3.1 million (Q4 2024), and -$64.2 million (Q3 2024).